Skip to main content
Premium Trial:

Request an Annual Quote

Exonhit, Pfizer Collaborate on Alzheimer's Biomarkers

NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.

Exonhit's Genome-Wide SpliceArray platform will be used to identify progression and other biomarkers "that could segregate healthy elderly controls, patients with mild cognitive impairment … and patients with AD," the Paris-based company said.

Pfizer will provide samples from each of the three patient groups for the study.

Financial and other terms of the collaboration were not disclosed.

Exonhit's GWSA platform is a microarray-based technology that uses specific probe configuration to monitor RNA splice variants. It monitors known and predicted alternative RNA splicing events in about 21,000 human genes, Exonhit said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.